CONTEXT: Postmenopausal women have greater visceral adiposity compared with premenopausal women. Adipokines are associated with increased adiposity, insulin resistance, and atherosclerosis. OBJECTIVE: The objective of the study was to assess changes in adipokines and inflammatory markers through the menopausal transition and correlate them with changes in visceral adiposity. DESIGN AND SETTING: This was a prospective cohort study of women through the menopausal transition conducted at the University of Washington. PARTICIPANTS: Sixty-nine healthy women were followed up longitudinally from premenopausal (aged 45-55 yr) to postmenopausal status (aged 49-60 yr). OUTCOME: On premenopausal and postmenopausal visits, fasting blood was drawn for adiponectin, leptin, serum amyloid A (SAA), C-reactive protein (CRP), monocyte-chemotactic protein-1, tissue plasminogen activator antigen (tPA), IL-6, and TNF-alpha. Body composition measures were assessed by body mass index, whole-body dual x-ray absorptiometry scan, and computed tomography scan of the abdomen at the lumbar 4-5 level. RESULTS: Women had a statistically significant increase in SAA, tPA, monocyte-chemotactic protein-1, and adiponectin between the two measurement occasions (P = 0.04, P = 0.02, P = 0.001, and P < 0.001, respectively). The increase in intraabdominal fat was correlated positively with the change in SAA (r = 0.31, P = 0.02), CRP (r = 0.56, P < 0.001), tPA (r = 0.40, P = 0.002), and leptin (r = 0.41, P = 0.002) and negatively correlated with the change in adiponectin (r = -0.37, P = 0.005). After adjustment for change in sc abdominal fat, the correlation between change in CRP, tPA, leptin, and adiponectin remained significantly associated with change in intraabdominal fat. CONCLUSIONS: Women going through the menopausal transition have deleterious changes in inflammatory markers and adipokines that correlate with increased visceral adiposity.
CONTEXT: Postmenopausal women have greater visceral adiposity compared with premenopausal women. Adipokines are associated with increased adiposity, insulin resistance, and atherosclerosis. OBJECTIVE: The objective of the study was to assess changes in adipokines and inflammatory markers through the menopausal transition and correlate them with changes in visceral adiposity. DESIGN AND SETTING: This was a prospective cohort study of women through the menopausal transition conducted at the University of Washington. PARTICIPANTS: Sixty-nine healthy women were followed up longitudinally from premenopausal (aged 45-55 yr) to postmenopausal status (aged 49-60 yr). OUTCOME: On premenopausal and postmenopausal visits, fasting blood was drawn for adiponectin, leptin, serum amyloid A (SAA), C-reactive protein (CRP), monocyte-chemotactic protein-1, tissue plasminogen activator antigen (tPA), IL-6, and TNF-alpha. Body composition measures were assessed by body mass index, whole-body dual x-ray absorptiometry scan, and computed tomography scan of the abdomen at the lumbar 4-5 level. RESULTS:Women had a statistically significant increase in SAA, tPA, monocyte-chemotactic protein-1, and adiponectin between the two measurement occasions (P = 0.04, P = 0.02, P = 0.001, and P < 0.001, respectively). The increase in intraabdominal fat was correlated positively with the change in SAA (r = 0.31, P = 0.02), CRP (r = 0.56, P < 0.001), tPA (r = 0.40, P = 0.002), and leptin (r = 0.41, P = 0.002) and negatively correlated with the change in adiponectin (r = -0.37, P = 0.005). After adjustment for change in sc abdominal fat, the correlation between change in CRP, tPA, leptin, and adiponectin remained significantly associated with change in intraabdominal fat. CONCLUSIONS:Women going through the menopausal transition have deleterious changes in inflammatory markers and adipokines that correlate with increased visceral adiposity.
Authors: Birgit Gustafson; Ann Hammarstedt; Christian X Andersson; Ulf Smith Journal: Arterioscler Thromb Vasc Biol Date: 2007-09-06 Impact factor: 8.311
Authors: E Maury; K Ehala-Aleksejev; Y Guiot; R Detry; A Vandenhooft; S M Brichard Journal: Am J Physiol Endocrinol Metab Date: 2007-06-19 Impact factor: 4.310
Authors: MaryFran R Sowers; Rachel P Wildman; Peter Mancuso; Aimee D Eyvazzadeh; Carrie A Karvonen-Gutierrez; Eileen Rillamas-Sun; Mary L Jannausch Journal: Maturitas Date: 2008-02-14 Impact factor: 4.342
Authors: Karen A Matthews; Laura L Schott; Joyce Bromberger; Jill Cyranowski; Susan A Everson-Rose; Mary Fran Sowers Journal: Psychosom Med Date: 2007-02-08 Impact factor: 4.312
Authors: Alfred O Mueck; Andrea R Genazzani; Göran Samsioe; Ivana Vukovic-Wysocki; Harald Seeger Journal: Menopause Date: 2007 Nov-Dec Impact factor: 2.953
Authors: S Perrini; L Laviola; A Cignarelli; M Melchiorre; F De Stefano; C Caccioppoli; A Natalicchio; M R Orlando; G Garruti; M De Fazio; G Catalano; V Memeo; R Giorgino; F Giorgino Journal: Diabetologia Date: 2007-10-25 Impact factor: 10.122
Authors: Siobán D Harlow; Margery Gass; Janet E Hall; Roger Lobo; Pauline Maki; Robert W Rebar; Sherry Sherman; Patrick M Sluss; Tobie J de Villiers Journal: J Clin Endocrinol Metab Date: 2012-02-16 Impact factor: 5.958
Authors: Kathryn E Davis; Michael D Neinast; Kai Sun; William M Skiles; Jessica D Bills; Jordan A Zehr; Daniel Zeve; Lisa D Hahner; Derek W Cox; Lana M Gent; Yong Xu; Zhao V Wang; Sohaib A Khan; Deborah J Clegg Journal: Mol Metab Date: 2013-06-04 Impact factor: 7.422
Authors: Jennifer W Bea; Ellen C Cussler; Scott B Going; Robert M Blew; Lauve L Metcalfe; Timothy G Lohman Journal: Med Sci Sports Exerc Date: 2010-07 Impact factor: 5.411